Credits: Canva
A recent study suggests that people who donate blood regularly may have genetic changes in their blood that could in fact reduce the risk of developing cancer. It is conducted by the researchers at the Francis Crick Institute, and the study has now provided new insights into how and why blood cancers develop. The study is published in the journal Blood and was conducted by the scientists from Heidelberg and the German Red Cross blood donation center. There is yet a need for further research to confirm these findings.
The researchers examined the blood of two groups of healthy male donors in their 60s:
The goal was to analyze genetic mutations in their blood and assess whether frequent donation had any impact on their genetic makeup.
As and when people age, their blood and other cells naturally develop mutations and some of them can also increase the risk of cancer. When anyone donates blood, his or her body compensates by producing new blood cells, which can influence the genetic diversity of stem cells in the bone marrow. The study also found that both groups had a similar number of mutations. For instance the frequent donors had 217 mutations, while the irregular donors had 212 mutations.
However, the nature of these mutations differed. In the frequent donors, 50% of the mutations were of a type not associated with a high risk of blood cancers, compared to only 30% in the irregular donors.
Further laboratory analysis showed that these specific mutations behaved differently from those linked to leukemia, a type of blood cancer. When human blood stem cells with these mutations were injected into mice, they were found to be highly effective at producing red blood cells, which is considered a positive outcome.
Dr. Hector Huerga Encabo, one of the study authors, emphasized that these mutations do not indicate an increased risk of leukemia. The findings suggest that regular blood donation may influence how stem cells evolve, but whether this translates into a lower cancer risk remains uncertain.
Read More: Who Can Donate Blood To Whom?
One notable disadvantage is the "healthy-donor effect"—because blood donors are often healthier than the general population, their lower cancer risk could be unrelated to blood donation.
Dominique Bonnet, senior researcher and head of a stem-cell laboratory at the Francis Crick Institute, stressed the need for larger studies with female volunteers to confirm the findings.
Despite ongoing research into potential health benefits for donors, the primary goal of blood donation remains saving lives. NHS Blood and Transplant emphasized that while the study is interesting, further research is required to draw firm conclusions. The organization also noted that blood supplies are currently critically low and encouraged eligible individuals to donate.
Also Read: How Long After a Tattoo or Piercing Can I Donate Blood?
Credit: iStock
Low-dose naltrexone has received plenty of attention as a strong candidate for treating people with chronic fatigue after COVID-19. But a new randomised clinical trial has found no significant improvement in fatigue, pain or any other symptoms when compared to a placebo.
The study, posted on medRxiv, examined low-dose naltrexone (LDN) in adults with post-COVID fatigue syndrome. The findings challenge hopes that an existing repurposed drug could provide relief for people whose symptoms have not subsided months after infection.
The paper has not yet undergone peer review, which means its findings have not been independently evaluated in a formal manner.
160 adults aged 19 to 69 from British Columbia and Ontario, Canada participated in the trial. Participants had developed symptoms that resembled myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) after a SARS-CoV-2 infection.
Researchers randomly assigned participants either low-dose naltrexone or a placebo for 16 weeks. The naltrexone dose began at 1 milligram daily and increased to a maximum of 4.5 milligrams, depending on how participants tolerated the treatment.
The main outcome was fatigue severity, which was measured using the Fatigue Severity Scale. At the end of the study, the average fatigue score was 4.2 in the LDN group and 4.4 in the placebo group.
The difference between the groups was not statistically significant, meaning the trial proved that the drug did not improve fatigue.
Researchers also found no significant differences between the groups in pain, overall ME/CFS symptoms, daily step counts or any other health aspects related to quality of life.
These results suggest that LDN did not provide any measurable benefit for the participants. The study also found that LDN was generally well tolerated over the 16-week period.
However, adverse events classified as grade 3 or higher were reported in five participants in the LDN group, or 6.2%, compared with three participants in the placebo group or 3.8%.
Also read: 'I Never Recovered From That Crash': US Physicist Recalls Her Years-Long Battle With Long COVID
Naltrexone is an established medicine used at standard doses to treat alcohol use disorder and opioid use disorder. At much lower doses, it has been tested for conditions involving chronic pain, inflammation and fatigue.
LDN’s effects on immune signalling and inflammatory conditions have sparked interest in its potential use for long COVID, a condition that can involve fatigue, cognitive difficulties, pain, breathlessness and symptoms affecting several biological functions.
The findings apply specifically to adults with post-COVID fatigue syndrome who met the study’s criteria for ME/CFS-like symptoms.
Long COVID refers to symptoms that occur after a SARS-CoV-2 infection and cannot be explained by another diagnosis. Symptoms vary widely and may include fatigue, cognitive difficulties, breathlessness, sleep disturbances and problems with everyday activities.
Some people improve over time, while others experience prolonged illness that affects their ability to lead routine lives.
The results do not mean that long COVID symptoms are untreatable. Instead, they highlight how difficult it can be to identify effective treatments for a condition with varied symptoms.
There are currently no FDA-approved medicines specifically for long COVID, and care often focuses on managing individual symptoms.
People taking or considering naltrexone should discuss its benefits and risks with a healthcare professional rather than starting or changing treatment on their own.
Credit: iStock
Low-dose aspirin could play a key role in lowering the risk of dementia significantly in some older adults, according to a new genetic analysis. However, the benefit does not come without a complication: major bleeding.
The study, led by researchers at Monash University in Australia, is based on data from more than 13,500 participants in the ASPREE trial, which investigated the effects of low-dose aspirin in older adults. The study was published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.
Researchers found that the benefit was mostly seen among people with a specific genetic trait linked with platelet count.
Platelets are small blood components that help form clots and stop bleeding. Researchers have previously examined how aggregation of platelets might contribute to dementia, but the role of genetically influenced platelet counts still remains unclear.
The researchers examined genetic scores related to platelet count and compared dementia results among participants who were either assigned aspirin or placebo.
Among people in the highest 20% of platelet count genetic scores, dementia developed in 1% of those taking aspirin, compared with 3.3% of those receiving a placebo. This represented approximately a 70% lower risk.
Lead author Dr Peter Fransquet, a research fellow at Monash University's School of Public Health and Preventive Medicine, said, “Previous trials found aspirin didn't prevent dementia when everyone was considered together.”
“Our findings suggest there may be more to the story,” he said.
Also read: Trump Says He ‘Psychologically’ Needs To Pop Aspirin Every Day: But Is It Actually Safe?
The benefit was accompanied by a safety concern. Among participants in the same genetic subgroup, major bleeding occurred in 4.4% of those assigned to aspirin, compared to 2.1% of those given a placebo. That is a difference of 2.3 percentage points in both dementia cases and major bleeding events. In other words, the lower dementia rate cannot be considered in isolation from the increased bleeding risk.
Aspirin reduces the ability of platelets to form clots. This can be useful for certain people who need to take precaution against cardiovascular events, but it can also increase the risk of serious bleeding, including bleeding in the gastrointestinal tract or brain.
The study therefore does not prove that aspirin offers a favourable overall balance of benefits and harms for people with this genetic profile.
The researchers found that the genetic signal was not linked to established genetic risk factors for Alzheimer's disease and dementia. Instead, it pointed towards platelet factor as a possible direction for further research.
“What's particularly interesting is that the signal wasn't linked to the established genetic risk factors for Alzheimer's disease and dementia,” Fransquet said. “Instead, it's pointing us towards platelet biology and gives us a new avenue to investigate.”
The findings could contribute to more personalised approaches to dementia prevention, in which treatments are tailored to characteristics that influence how individuals respond. But the results need to be replicated in other populations and tested in a clinical trial specifically designed for people with the identified genetic profile.
Fransquet said, “People shouldn’t start taking aspirin to prevent dementia on the basis of this study without consulting with their doctor, particularly given the increased risk of serious bleeding,” he said.
Credit: AI
High blood pressure can be managed with medication and dietary changes. But recent research suggests that certain mental health habits can also help fight hypertension.
Mental health practices like mindfulness, optimism and gratitude may also support cardiovascular health, partly by helping people manage stress better and maintain healthier habits.
Hypertension affects nearly half of adults in the United States. While lifestyle changes like reducing salt intake, exercising regularly, maintaining a healthy weight and limiting alcohol remain crucial, the emerging study says that psychological wellbeing can also have a beneficial effect on blood pressure.
“Stress contributes to hypertension,” said Willie E. Lawrence Jr., a cardiologist and spokesperson for the American Heart Association. “It’s hard to get all the stress out of your life, but there are things that you can do to lower blood pressure, like mindfulness.”
According to the researchers, here are three mental health habits that may help:
Mindfulness refers to paying attention to thoughts, emotions and physical sensations in the present moment without judging them. It may help alleviate stress and improve behaviours that affect blood pressure like dietary choices and physical activity.
Eric Loucks, professor of epidemiology and director of the Mindfulness Center at Brown University, developed a mindfulness-based blood pressure reduction programme that teaches participants all about self-awareness, attention control and emotional regulation. The programme teaches people to apply these skills to everyday decisions like choosing healthier foods.
“There can be energy that comes up to act on those insights,” Loucks said. “So if we decide we want to eat more healthily, can we be there with that energy in the grocery store, selecting the food for the week?”
Also read: Eating A Handful Of Nuts Daily May Lower High Blood Pressure Risk, Study Finds
Optimism means expecting positive outcomes while recognising that challenges exist. Research has linked an optimistic outlook with better cardiovascular health, but evidence that it lowers blood pressure in people who already have hypertension is limited.
A study based on more than 100,000 active-duty US Army personnel without hypertension found that the most optimistic participants were less likely to develop high blood pressure during an average follow-up of three and a half years.
Julia Boehm, professor and chair of psychology at Chapman University said that practising optimism does not mean ignoring difficulties. Instead, people can identify realistic, achievable actions that support their health, such as choosing nutritious meals or becoming more physically active.
“This might mean something concrete like, ‘Am I going to choose to eat the salad or the french fries at lunch?’ and thinking optimistically that my choices in any given moment are going to translate into measurable effects in the long run,” Boehm said.
Gratitude involves acknowledging the people, experiences and acts one appreciates. Some research suggests it may affect cardiovascular responses to stress.
One study found that writing a gratitude letter changed how systolic blood pressure responded during a stress test. Systolic pressure, the upper number in a blood pressure reading, measures pressure when the heart contracts.
Mindfulness, optimism and gratitude should complement established hypertension treatment, not replace it. Medication, regular physical activity, a balanced diet and screening remain essential.
As Boehm cautioned, “You can’t ignore the doctor’s advice to either take your medications or engage in physical activity or eat fruits and vegetables. It’s just one piece of a larger strategy to bolster health.”
© $2026 Times Horizon Private Limited